SGLT2 inhibitor treatment significantly reduces the expression of inflammatory markers TNF-α, IL-1β, and IL-6, thereby delaying the occurrence and progression of atherosclerosis (115). The gene discussed is SLC5A2; the disease is atherosclerosis.